Grace Therapeutics (GRCE) Competitors $3.03 +0.01 (+0.33%) As of 10/3/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRCE vs. NLTX, GNLX, CTOR, ACTU, CRBP, ELDN, THTX, TVGN, CYBN, and SAVAShould you be buying Grace Therapeutics stock or one of its competitors? The main competitors of Grace Therapeutics include Neoleukin Therapeutics (NLTX), Genelux (GNLX), Citius Oncology (CTOR), Actuate Therapeutics (ACTU), Corbus Pharmaceuticals (CRBP), Eledon Pharmaceuticals (ELDN), Theratechnologies (THTX), Tevogen Bio (TVGN), Cybin (CYBN), and Cassava Sciences (SAVA). These companies are all part of the "pharmaceutical products" industry. Grace Therapeutics vs. Its Competitors Neoleukin Therapeutics Genelux Citius Oncology Actuate Therapeutics Corbus Pharmaceuticals Eledon Pharmaceuticals Theratechnologies Tevogen Bio Cybin Cassava Sciences Neoleukin Therapeutics (NASDAQ:NLTX) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk. Which has higher earnings and valuation, NLTX or GRCE? Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-7.18Grace TherapeuticsN/AN/A-$9.57M-$0.86-3.52 Which has more volatility & risk, NLTX or GRCE? Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Grace Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500. Do analysts rate NLTX or GRCE? Grace Therapeutics has a consensus target price of $12.00, indicating a potential upside of 296.04%. Given Grace Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Grace Therapeutics is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Grace Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is NLTX or GRCE more profitable? Grace Therapeutics' return on equity of -20.36% beat Neoleukin Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% Grace Therapeutics N/A -20.36%-18.09% Does the media favor NLTX or GRCE? In the previous week, Grace Therapeutics had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for Grace Therapeutics and 0 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.00 beat Grace Therapeutics' score of -1.00 indicating that Neoleukin Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Neoleukin Therapeutics Neutral Grace Therapeutics Negative Do insiders and institutionals have more ownership in NLTX or GRCE? 52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 11.1% of Grace Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryGrace Therapeutics beats Neoleukin Therapeutics on 10 of the 13 factors compared between the two stocks. Get Grace Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRCE vs. The Competition Export to ExcelMetricGrace TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.83M$3.36B$6.14B$10.58BDividend YieldN/A2.28%5.67%4.69%P/E Ratio-3.5222.1478.0526.70Price / SalesN/A458.33605.13131.81Price / CashN/A47.8637.9061.31Price / Book0.629.9312.556.55Net Income-$9.57M-$52.80M$3.31B$277.50M7 Day Performance-1.94%5.22%4.28%2.41%1 Month Performance-0.98%13.01%7.85%9.30%1 Year PerformanceN/A25.18%71.37%31.22% Grace Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRCEGrace Therapeutics2.0635 of 5 stars$3.03+0.3%$12.00+296.0%N/A$41.83MN/A-3.52N/ANegative NewsShort Interest ↑NLTXNeoleukin TherapeuticsN/A$17.98+3.7%N/A-52.8%$168.93MN/A-5.7890High Trading VolumeGNLXGenelux1.6027 of 5 stars$4.39-0.2%$20.33+363.2%+91.0%$166.20MN/A-5.1010News CoveragePositive NewsCTORCitius Oncology3.23 of 5 stars$1.88-4.6%$6.00+219.1%+60.2%$164.52MN/A0.00N/AShort Interest ↓ACTUActuate Therapeutics1.4831 of 5 stars$6.69-3.5%$20.33+203.9%+1.7%$161.08MN/A0.0010CRBPCorbus Pharmaceuticals4.1453 of 5 stars$13.01-0.2%$45.43+249.2%-25.5%$159.81MN/A-2.7340ELDNEledon Pharmaceuticals2.361 of 5 stars$2.76+3.8%$10.00+262.3%+11.4%$159.29MN/A-2.3610THTXTheratechnologiesN/A$3.42+0.9%N/A+183.2%$157.21M$84.38M-17.99140Upcoming EarningsHigh Trading VolumeTVGNTevogen Bio3.3393 of 5 stars$0.78-2.2%$10.00+1,183.0%+121.2%$156.77MN/A-4.103Gap DownCYBNCybin2.263 of 5 stars$6.21+3.8%$85.00+1,268.8%-31.1%$156.42MN/A-1.4250High Trading VolumeSAVACassava Sciences2.8994 of 5 stars$3.43+7.2%$2.00-41.7%-86.5%$154.59MN/A-1.3530News CoveragePositive News Related Companies and Tools Related Companies Neoleukin Therapeutics Alternatives Genelux Alternatives Citius Oncology Alternatives Actuate Therapeutics Alternatives Corbus Pharmaceuticals Alternatives Eledon Pharmaceuticals Alternatives Theratechnologies Alternatives Tevogen Bio Alternatives Cybin Alternatives Cassava Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRCE) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grace Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grace Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRCE Stock Alerts